Johnson & Johnson
JNJ,
-0.19%
said Thursday that its lead vaccine candidate protected against infection with SARS-CoV-2, the virus that causes COVID-19, in pre-clinical studies. The vaccine…
Read More
Please follow and like us:
Categories
Johnson & Johnson starts trial of COVID-19 vaccine after producing immune response in primates – MarketWatch
Johnson & Johnson JNJ, -0.19% said Thursday that its lead vaccine candidate protected against infection with SARS-CoV-2, the virus that causes COVID-19, in pre-clinical studies. The vaccine…
